Uncertainty Surrounding R&D Outcomes and Risks Related to Securing and Developing Highly Skilled Personnel
First written in FY2017. 5 of 8 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 15 of 32 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2025Research and development expenditure of ¥3,267 million disclosedAnnual report
「Research and development expenses included in selling, general and administrative expenses and manufacturing costs for the current period amounted to ¥3,267 million, representing approximately 6% of consolidated net sales.」
Recognition of the risks associated with uncertain R&D outcomes and dependence on highly skilled personnel continues. Research and development expenses were disclosed as ¥3,267 million, or approximately 6% of net sales. - FY2024Research and development expense ratio changed to approximately 6%.Annual report
「Research and development expenses included in selling, general and administrative expenses and manufacturing costs for the current period amounted to ¥3,127 million, representing approximately 6% of consolidated net sales. However, the results of research and development are uncertain, and there is a risk that substantial expenditures may not necessarily lead to results.」
The uncertainty of R&D outcomes and dependence on highly skilled personnel continue. While research and development expenses increased, the ratio of spending to net sales was stated to have declined from approximately 7% to approximately 6%. - FY2023RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and manufacturing costs for the current period amounted to ¥2,967 million, representing approximately 7% of consolidated net sales. However, the results of research and development are uncertain, and there is a risk that substantial expenditures may not necessarily lead to results.」
Research and development expenses amounted to ¥2,967 million, or approximately 7% of net sales, and the disclosure continues to address the uncertainty of R&D outcomes and the risk of securing and developing technical personnel. quantified=true, materialized=false. - FY2022RestatedAnnual report
「Research and development expenditure included in selling, general and administrative expenses and manufacturing costs was ¥2,807 million, equivalent to approximately 7% of consolidated net sales. However, research and development outcomes are uncertain, and there is a risk that even substantial expenditure may not necessarily lead to results.」
The Company continues to identify uncertainty surrounding outcomes and the risk of securing and developing research and development personnel while investing approximately 7% of sales in research and development expenditure. - FY2021RestatedAnnual report
「Research and development expenditure included in selling, general and administrative expenses and manufacturing costs was ¥2,845 million, equivalent to approximately 7% of consolidated net sales. However, research and development outcomes are uncertain, and there is a risk that even substantial expenditure may not necessarily lead to results.」
The Company continues to identify uncertainty surrounding outcomes and dependence on securing and developing technical personnel as risks while investing approximately 7% of sales in research and development expenditure. - FY2020RestatedAnnual report
「Research and development expenditure included in selling, general and administrative expenses and manufacturing costs was ¥3,058 million, equivalent to approximately 7% of consolidated net sales. However, research and development outcomes are uncertain, and there is a risk that even substantial expenditure may not necessarily lead to results. In addition, the Group's growth depends particularly on capable personnel engaged in research and development, making it important to secure and develop personnel with strong technical skills and to appropriately evaluate research outcomes.」
The Company continues to identify uncertainty surrounding outcomes and dependence on securing and developing technical personnel as risks while investing approximately 7% of sales in research and development expenditure. - FY2019RestatedAnnual report
「Research and development expenditure included in selling, general and administrative expenses and current manufacturing costs was ¥3,209 million, equivalent to approximately 7% of consolidated net sales. However, research and development outcomes are uncertain, and there is a risk that even substantial expenditure may not necessarily lead to results. In addition, the Group's growth depends particularly on capable personnel engaged in research and development, making it important to secure and develop personnel with strong technical skills and to appropriately evaluate research outcomes.」
The Company continues to explain that, despite investing approximately 7% of sales in research and development expenditure, uncertainty surrounding outcomes and dependence on technical personnel constitute risks. - FY2017First statedAnnual report
「Research and development expenditure included in selling, general and administrative expenses and current manufacturing costs was ¥3,042 million, equivalent to approximately 7% of consolidated net sales. However, research and development outcomes are uncertain, and there is a risk that even substantial expenditure may not necessarily lead to results. In addition, the Group's growth depends particularly on capable personnel engaged in research and development, making it important to secure and develop personnel with strong technical skills and to appropriately evaluate research outcomes.」
While investing approximately 7% of sales in research and development expenditure, the Company identifies uncertainty surrounding outcomes and dependence on securing and developing technical personnel as risks.